Sage Capital Advisors’s Dermata Therapeutics DRMA Stock Holding History

Sage Capital Advisors’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5	Closed	-$4.91K	–	131
2022 Q4	$4.91K	Hold	5	–	–	﹤0.01%	127
2022 Q3	$6K	Hold	5	–	–	﹤0.01%	117
2022 Q2	$8K	Buy	+5	New	+$10.3K	﹤0.01%	106
2022 Q1	–	Sell	-5	Closed	-$20K	–	110
2021 Q4	$20K	Buy	+5	New	+$44.2K	0.01%	106

Other funds holding DRMA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sage Capital Advisors's DRMA Position: Q1 2023 in Review

Sage Capital Advisors sold out of Dermata Therapeutics (DRMA) in Q1 2023, closing a stake of 5 shares — an estimated $4.91K sold.

Sage Capital Advisors first reported a position in DRMA in Q4 2021 and held it in 4 quarters. The position peaked at $20K in Q4 2021. 4 funds tracked by Wall St. Rank hold DRMA as of Q1 2023.

Sage Capital Advisors reported no remaining Dermata Therapeutics position as of Q1 2023 after selling out during the quarter.
Sage Capital Advisors sold 5 Dermata Therapeutics shares in Q1 2023, an estimated $4.91K.
Sage Capital Advisors first reported a position in Dermata Therapeutics in Q4 2021 and held it in 4 quarters.
Sage Capital Advisors's Dermata Therapeutics position peaked at $20K in Q4 2021.
4 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q1 2023.

Based on Sage Capital Advisors's 13F filing for Q1 2023, filed 11 Apr 2023.